RAPT Therapeutics (RAPT) has released an update.
RAPT Therapeutics, Inc. faces a setback as the FDA has verbally notified the company of a clinical hold on its Phase 2b and Phase 2a trials for zelnecirnon in atopic dermatitis and asthma, respectively. The formal notice is forthcoming. The company is actively seeking a resolution and will only update the public when there are significant developments.
For further insights into RAPT stock, check out TipRanks’ Stock Analysis page.
